Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.

Rinschen MM, Schermer B, Benzing T.

J Am Soc Nephrol. 2014 Jun;25(6):1140-7. doi: 10.1681/ASN.2013101037. Epub 2014 Feb 20. Review.

2.

Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease.

Devuyst O, Torres VE.

Curr Opin Nephrol Hypertens. 2013 Jul;22(4):459-70. doi: 10.1097/MNH.0b013e3283621510. Review.

3.

Role of vasopressin antagonists.

Torres VE.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1212-8. doi: 10.2215/CJN.05281107. Epub 2008 Apr 23. Review.

4.

Review of tolvaptan for autosomal dominant polycystic kidney disease.

Baur BP, Meaney CJ.

Pharmacotherapy. 2014 Jun;34(6):605-16. doi: 10.1002/phar.1421. Epub 2014 Apr 7. Review.

PMID:
24706579
5.

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.

Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15.

PMID:
25600953
6.

PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice.

Ahrabi AK, Terryn S, Valenti G, Caron N, Serradeil-Le Gal C, Raufaste D, Nielsen S, Horie S, Verbavatz JM, Devuyst O.

J Am Soc Nephrol. 2007 Jun;18(6):1740-53. Epub 2007 May 2.

7.

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.

Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS.

Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17.

PMID:
21333426
8.

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors.

Juul KV, Bichet DG, Nielsen S, Nørgaard JP.

Am J Physiol Renal Physiol. 2014 May 1;306(9):F931-40. doi: 10.1152/ajprenal.00604.2013. Epub 2014 Mar 5. Review.

9.

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS.

Kidney Int. 2011 Aug;80(3):295-301. doi: 10.1038/ki.2011.119. Epub 2011 May 4.

10.

Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?

Janssens P, Weydert C, De Rechter S, Wissing KM, Liebau MC, Mekahli D.

Pediatr Nephrol. 2018 Mar;33(3):395-408. doi: 10.1007/s00467-017-3672-x. Epub 2017 Apr 28. Review.

PMID:
28455745
11.

Increased renal responsiveness to vasopressin and enhanced V2 receptor signaling in RGS2-/- mice.

Zuber AM, Singer D, Penninger JM, Rossier BC, Firsov D.

J Am Soc Nephrol. 2007 Jun;18(6):1672-8. Epub 2007 May 2.

12.

Calmodulin-sensitive adenylyl cyclases mediate AVP-dependent cAMP production and Cl- secretion by human autosomal dominant polycystic kidney cells.

Pinto CS, Reif GA, Nivens E, White C, Wallace DP.

Am J Physiol Renal Physiol. 2012 Nov 15;303(10):F1412-24. doi: 10.1152/ajprenal.00692.2011. Epub 2012 Sep 5.

13.

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.

Boertien WE, Meijer E, de Jong PE, Bakker SJ, Czerwiec FS, Struck J, Oberdhan D, Shoaf SE, Krasa HB, Gansevoort RT.

Kidney Int. 2013 Dec;84(6):1278-86. doi: 10.1038/ki.2013.285. Epub 2013 Jul 31.

14.

Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.

Blair HA, Keating GM.

Drugs. 2015 Oct;75(15):1797-806. doi: 10.1007/s40265-015-0475-x. Review.

PMID:
26407729
15.

Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.

Harskamp LR, Gansevoort RT, Boertien WE, van Oeveren W, Engels GE, van Goor H, Meijer E.

Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1749-56. doi: 10.2215/CJN.09941014. Epub 2015 Jul 31.

17.

[Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].

Cornec-Le Gall E, Le Meur Y.

Nephrol Ther. 2014 Nov;10(6):433-40. doi: 10.1016/j.nephro.2014.03.003. Epub 2014 Jul 30. Review. French.

PMID:
25086476
18.

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS.

J Am Soc Nephrol. 2017 May;28(5):1592-1602. doi: 10.1681/ASN.2016040448. Epub 2016 Dec 5.

19.

Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back.

Devuyst O, Wang X, Serra A.

Nephrol Dial Transplant. 2011 Aug;26(8):2423-5. doi: 10.1093/ndt/gfr380. No abstract available.

20.

Supplemental Content

Support Center